Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma

Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma Pembrolizumab is a programmed death (PD)‐1 receptor inhibitor and a first‐line treatment for unresectable metastatic melanoma (MM) that is displaying disease progression following treatment with ipilimumab or a BRAF inhibitor. The extent of the dermatological adverse effects (AEs) associated with pembrolizumab has not been fully established. Belum et al. reported that the commonest AEs associated with PD‐1 receptor inhibitors are vitiligo, rash and pruritus, occurring in approximately 8–20% of patients. Given the immunomodulatory nature of PD‐1 receptor inhibitors, the aetiology of these symptoms is considered immune‐mediated, but this is unproven. We report a case of lichen planus (LP) developing during treatment with pembrolizumab.A 46‐year‐old man with atypical naevus syndrome re‐presented with MM in December 2013, 16 years after having two previous melanomas removed and undergoing right axillary node clearance. He reported evolving masses in his right axilla and thigh; subsequent imaging confirmed disease at these areas, along with nodules at the border of the right pulmonary trunk and the hemi‐diaphragm. Histological biopsy of the axillary lesion confirmed the presence of metastatic disease, and dacarbazine was commenced for stage IV MM. The patient received two cycles of treatment before being switched to ipilimumab (patient was negative for BRAF‐V600E mutation) in June 2014 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical & Experimental Dermatology Wiley

Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma

Loading next page...
 
/lp/wiley/lichen-planus-in-a-patient-treated-with-pembrolizumab-for-metastatic-fqvbFeSuMe
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 British Association of Dermatologists
ISSN
0307-6938
eISSN
1365-2230
D.O.I.
10.1111/ced.13315
Publisher site
See Article on Publisher Site

Abstract

Pembrolizumab is a programmed death (PD)‐1 receptor inhibitor and a first‐line treatment for unresectable metastatic melanoma (MM) that is displaying disease progression following treatment with ipilimumab or a BRAF inhibitor. The extent of the dermatological adverse effects (AEs) associated with pembrolizumab has not been fully established. Belum et al. reported that the commonest AEs associated with PD‐1 receptor inhibitors are vitiligo, rash and pruritus, occurring in approximately 8–20% of patients. Given the immunomodulatory nature of PD‐1 receptor inhibitors, the aetiology of these symptoms is considered immune‐mediated, but this is unproven. We report a case of lichen planus (LP) developing during treatment with pembrolizumab.A 46‐year‐old man with atypical naevus syndrome re‐presented with MM in December 2013, 16 years after having two previous melanomas removed and undergoing right axillary node clearance. He reported evolving masses in his right axilla and thigh; subsequent imaging confirmed disease at these areas, along with nodules at the border of the right pulmonary trunk and the hemi‐diaphragm. Histological biopsy of the axillary lesion confirmed the presence of metastatic disease, and dacarbazine was commenced for stage IV MM. The patient received two cycles of treatment before being switched to ipilimumab (patient was negative for BRAF‐V600E mutation) in June 2014

Journal

Clinical & Experimental DermatologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off